📊 KPTI Key Takeaways
Is Karyopharm Therapeutics Inc. (KPTI) a Good Investment?
Karyopharm is technically insolvent with negative stockholders' equity of -$292.9M and liabilities exceeding assets by $292.9M. The company is burning $75.4M annually with only $60.5M in cash, providing approximately 9-10 months of runway. With flat revenue growth (+0.6% YoY), massive operating losses (-$90.7M), and inability to service debt from operations (interest coverage -6.1x), the company faces imminent solvency crisis without significant capital infusion.
Revenue is essentially flat while profitability remains deeply negative, with operating and net margins of -62% and -134% and ROA of -181% signaling severe losses relative to a small asset base. Negative shareholders’ equity, weak interest coverage, and only modest liquidity (current ratio ~1.1) create acute solvency and refinancing risk without rapid margin improvement or new capital. Persistent negative free cash flow (-52% margin) points to ongoing burn and potential dilution or restructuring pressure.
Why Buy Karyopharm Therapeutics Inc. Stock? KPTI Key Strengths
- Maintains $60.5M cash position providing near-term liquidity buffer
- Established revenue base of $146.1M demonstrates product market presence
- Operating in pharmaceutical sector with potential undisclosed pipeline assets
- Established commercial revenue base (~$146M) with slight YoY growth
- Capex‑light model offering operating flexibility if margins improve
- Current ratio above 1x provides a limited short‑term buffer
KPTI Stock Risks: Karyopharm Therapeutics Inc. Investment Risks
- Negative stockholders' equity of -$292.9M indicates technical insolvency
- Unsustainable cash burn of $75.4M annually with only 9-10 months of runway at current rate
- Operating losses of -$90.7M on $146.1M revenue with no profitability trajectory visible
- Cannot service $169.3M debt burden from operations (interest coverage -6.1x)
- Flat revenue growth (+0.6% YoY) coupled with expanding losses signals deteriorating business model
- Likely requires dilutive financing that would further impair equity holders
- Negative equity and liabilities far exceeding assets indicate solvency risk
- Sustained cash burn and negative interest coverage imply dependence on financing/dilution
- Flat top‑line limits operating leverage and delays path to break‑even
Key Metrics to Watch
- Monthly cash burn rate and months of runway remaining
- Revenue growth by product segment and new product commercialization
- Operating expense trends and path to operating profitability
- Debt covenant compliance status and refinancing/restructuring needs
- Operating cash flow inflection point
- Operating cash flow (burn/runway)
- Operating margin
Karyopharm Therapeutics Inc. (KPTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Karyopharm Therapeutics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
KPTI Profit Margin, ROE & Profitability Analysis
KPTI vs Healthcare Sector: How Karyopharm Therapeutics Inc. Compares
How Karyopharm Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Karyopharm Therapeutics Inc. Stock Overvalued? KPTI Valuation Analysis 2026
Based on fundamental analysis, Karyopharm Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Karyopharm Therapeutics Inc. Balance Sheet: KPTI Debt, Cash & Liquidity
KPTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Karyopharm Therapeutics Inc.'s revenue has declined by 30% over the 5-year period, indicating business contraction. The most recent EPS of $-18.79 indicates the company is currently unprofitable.
KPTI Revenue Growth, EPS Growth & YoY Performance
KPTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $38.8M | -$32.1M | $-3.82 |
| Q2 2025 | $37.9M | -$13.6M | $-2.97 |
| Q1 2025 | $30.0M | -$23.5M | $-2.77 |
| Q3 2024 | $36.0M | -$32.1M | $-0.26 |
| Q2 2024 | $37.6M | -$13.6M | $-0.20 |
| Q1 2024 | $33.1M | -$34.1M | $-0.30 |
| Q3 2023 | $36.0M | -$34.5M | $-0.30 |
| Q2 2023 | $37.6M | -$32.6M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Karyopharm Therapeutics Inc. Dividends, Buybacks & Capital Allocation
KPTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Karyopharm Therapeutics Inc. (CIK: 0001503802)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KPTI
What is the AI rating for KPTI?
Karyopharm Therapeutics Inc. (KPTI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KPTI's key strengths?
Claude: Maintains $60.5M cash position providing near-term liquidity buffer. Established revenue base of $146.1M demonstrates product market presence. ChatGPT: Established commercial revenue base (~$146M) with slight YoY growth. Capex‑light model offering operating flexibility if margins improve.
What are the risks of investing in KPTI?
Claude: Negative stockholders' equity of -$292.9M indicates technical insolvency. Unsustainable cash burn of $75.4M annually with only 9-10 months of runway at current rate. ChatGPT: Negative equity and liabilities far exceeding assets indicate solvency risk. Sustained cash burn and negative interest coverage imply dependence on financing/dilution.
What is KPTI's revenue and growth?
Karyopharm Therapeutics Inc. reported revenue of $146.1M.
Does KPTI pay dividends?
Karyopharm Therapeutics Inc. does not currently pay dividends.
Where can I find KPTI SEC filings?
Official SEC filings for Karyopharm Therapeutics Inc. (CIK: 0001503802) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KPTI's EPS?
Karyopharm Therapeutics Inc. has a diluted EPS of $-17.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KPTI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Karyopharm Therapeutics Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KPTI stock overvalued or undervalued?
Valuation metrics for KPTI: ROE of N/A (sector avg: 15%), net margin of -134.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KPTI stock in 2026?
Our dual AI analysis gives Karyopharm Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KPTI's free cash flow?
Karyopharm Therapeutics Inc.'s operating cash flow is $-75.4M, with capital expenditures of $0.0. FCF margin is -51.6%.
How does KPTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -134.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.12 (avg: 2).